Q-omics provides the consensus-scored NCR2 profile across patient tissues and cancer cell-line models. NCR2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, NCR2 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, NCR2 RNA expression shows 6,558 significant pathway-activity associations, with the highest sampling consensus in THCA. Together, these results highlight BLCA, COAD, and THCA as cancer lineages where NCR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NCR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NCR2 survival associations across molecular data types. NCR2 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NCR2 RNA expression–survival associations across cancer types. High NCR2 expression shows unfavorable associations in LAML, ACC, HNSC and LUSC, but favorable associations in BLCA and READ. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify BLCA as the clearest survival context for NCR2 RNA expression.
This table summarizes NCR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NCR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NCR2 shows lower tumor expression in COAD and higher tumor expression in KIRP, KIRC, LUAD, KICH and LIHC. The COAD box plot shows higher NCR2 RNA expression in normal versus tumor tissue (log2 FC = −0.422, t-test p < 0.001).
This table shows molecular features associated with NCR2 in patient tissues and cancer cell lines. In patient samples, NCR2 shows the broadest associations at the RNA and protein expression levels, with THCA recurring as the lineage with the largest associated feature set. In cancer cell lines, NCR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LUNG_SCLC.
